Marinetrans Indi (MARINETRAN)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Quarterly revenue of ₹57 Cr is large relative to the ₹25 Cr market cap, giving the company a sizeable revenue base if margins ever recover.
• Profit growth of +6.90% despite a -27.79% sales decline suggests some cost discipline or margin improvement.
• Piotroski F-Score of 6/9 indicates moderately sound operational health, not a deeply distressed balance sheet.
• Price near ₹16.85, closer to the 52-week low than the high, offers a starting point for monitoring rather than chasing momentum.

Concerns

• Revenue declined 27.79% and the latest quarter net profit is effectively ₹0 Cr, so current earnings power is negligible.
• P/E of 43.09 and PEG of 6.24 imply an expensive valuation relative to very weak growth.
• ROCE of 5.48% is below an acceptable investment threshold, and a 0.00% dividend yield means no compensation while waiting.
• Critical data on book value, debt/equity, and promoter holding is missing, so an intrinsic value estimate cannot be made with confidence.

AI Analysis

At first glance, Marinetrans Indi fails the first test I apply to any business: can I understand its economics and does it earn a satisfactory return on capital? ROCE is only 5.48%; I could earn a similar return in a bank FD without worrying about quarterly results. The latest quarter shows sales of ₹57 crore but net profit of roughly zero. That is not earning power. Revenue has shrunk nearly 28%, while reported profit growth of 6.90% looks like cost-cutting, not genuine demand. A P/E of 43.09 and a PEG of 6.24 mean the market is paying a rich price for a very small, and currently absent, profit stream. The Piotroski score of 6/9 does suggest management has taken some corrective actions, but the balance sheet and promoter data are missing. In Graham's words, price is what you pay, value is what you get. At ₹16.85, near the 52-week low, the stock may look cheap, but a low price is no margin of safety if earnings are falling and returns on capital are low. Quarterly sales of ₹57 crore against a ₹25 crore market cap shows the firm has scale, but scale without margins is just a treadmill. I do not see a durable moat, pricing power, or visible growth. Until sales stabilise, ROCE moves into double digits, and the company demonstrates it can convert revenue into profits, this remains a speculative small-cap, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer